Best Practice & Research Clinical Rheumatology
Volume 20, Issue 6 , Pages 1045-1063 , December 2006

Prosthetic-joint-associated infections

  • Werner Zimmerli, MD (Head of Internal Medicine)

      Affiliations

    • Corresponding Author InformationTel.: +41 61 925 21 80; Fax: +41 61 925 28 04.

References 

  1. Darouiche RO. Treatment of infections associated with surgical implants. New England Journal of Medicine. 2004;350(14):1422–1429
  2. Zimmerli W, Trampuz A, Ochsner PE. Prosthetic joint infections. New England Journal of Medicine. 2004;351(16):1645–1654
  3. Costerton JW, Montanaro L, Arciola CR. Biofilm in implant infections: its production and regulation. International Journal of Artificial Organs. 2005;28(11):1062–1068
  4. Trampuz A, Piper K, Hanssen A, et al. Sonication of explanted prosthetic components in bags for diagnosis of prosthetic joint infection is associated with risk of contamination. Journal of Clinical Microbiology. 2006;441:628–631
  5. Trampuz A, Steckelberg J, Osmon D, et al. Advances in the laboratory diagnosis of prosthetic joint infection. Reviews in Medical Microbiology. 2003;14:1–14
  6. Brause B. Infections with prostheses in bones and joints. In:  Mandell GL,  Bennett JE,  Dolin R editor. Principles and Practice of Infectious Diseases. 6th edn. Washington, DC: WB Saunders; 2005;p. 1332–1337
  7. Ragni MV, Crossett LS, Herndon JH. Postoperative infection following orthopaedic surgery in human immunodeficiency virus-infected hemophiliacs with CD4 counts < or = 200/mm3. The Journal of Arthroplasty. 1995;10(6):716–721
  8. Wilson MG, Kelley K, Thornhill TS. Infection as a complication of total knee-replacement arthroplasty. Risk factors and treatment in sixty-seven cases. The Journal of Bone and Joint Surgery. American Volume. 1990;72(6):878–883
  9. Poss R, Thornhill TS, Ewald FC, et al. Factors influencing the incidence and outcome of infection following total joint arthroplasty. Clinical Orthopaedics and Related Research. 1984;(182):117–126
  10. Berbari EF, Hanssen AD, Duffy MC, et al. Risk factors for prosthetic joint infection: case-control study. Clinical Infectious Diseases. 1998;27(5):1247–1254
  11. Schafroth M, Zimmerli W, Brunazzi M, Ochsner PE. Infections. In:  Ochsner PE editors. Total Hip Replacement: Implantation Technique and Local Complications. Berlin: Springer; 2003;p. 65–90
  12. Ainscow DA, Denham RA. The risk of haematogenous infection in total joint replacements. The Journal of Bone and Joint Surgery. British Volume. 1984;66(4):580–582
  13. Murdoch DR, Roberts SA, Fowler VG, et al. Infection of orthopedic prostheses after Staphylococcus aureus bacteremia. Clinical Infectious Diseases. 2001;32(4):647–649
  14. Darouiche RO. Device-associated infections: a macroproblem that starts with microadherence. Clinical Infectious Diseases. 2001;33(9):1567–1572
  15. Zimmerli W, Waldvogel FA, Vaudaux P, Nydegger UE. Pathogenesis of foreign body infection: description and characteristics of an animal model. The Journal of Infectious Diseases. 1982;146(4):487–497
  16. Elek SD, Conen PE. The virulence of Staphylococcus pyogenes for man; a study of the problems of wound infection. British Journal of Experimental Pathology. 1957;38(6):573–586
  17. Giulieri SG, Graber P, Ochsner PE, Zimmerli W. Management of infection associated with total hip arthroplasty according to a treatment algorithm. Infection. 2004;32(4):222–228
  18. Laffer RR, Graber P, Ochsner PE, Zimmerli W. Outcome of prosthetic knee-associated infection: evaluation of 40 consecutive episodes at a single centre. Clinical Microbiology and Infection. 2006;12(5):433–439
  19. Zimmerli W, Lew PD, Waldvogel FA. Pathogenesis of foreign body infection. Evidence for a local granulocyte defect. The Journal of Clinical Investigation. 1984;73(4):1191–1200
  20. Ramage G, Tunney MM, Patrick S, et al. Formation of Propionibacterium acnes biofilms on orthopaedic biomaterials and their susceptibility to antimicrobials. Biomaterials. 2003;24(19):3221–3227
  21. Trampuz A, Osmon D, Hanssen A, et al. Molecular and antibiofilm approaches to prosthetic joint infection. Clinical Orthopaedics and Related Research. 2003;414:69–88
  22. Gotz F. Staphylococcus and biofilms. Molecular Microbiology. 2002;43(6):1367–1378
  23. Yao Y, Sturdevant DE, Otto M. Genomewide analysis of gene expression in Staphylococcus epidermidis biofilms: insights into the pathophysiology of S. epidermidis biofilms and the role of phenol-soluble modulins in formation of biofilms. The Journal of Infectious Diseases. 2005;191(2):289–298
  24. Williams RJ, Henderson B, Sharp LJ, Nair SP. Identification of a fibronectin-binding protein from Staphylococcus epidermidis. Infection and Immunity. 2002;70(12):6805–6810
  25. König D, Perdreau-Remington F, Rütt J, et al. Slime production of Staphylococcus epidermidis. Acta Orthopaedica Scandinavica. 1998;69:523–526
  26. Schwank S, Rajacic Z, Zimmerli W, Blaser J. Impact of bacterial biofilm formation on in vitro and in vivo activities of antibiotics. Antimicrobial Agents and Chemotherapy. 1998;42(4):895–898
  27. Davies DG, Parsek MR, Pearson JP, et al. The involvement of cell-to-cell signals in the development of a bacterial biofilm. Science. 1998;280(5361):295–298
  28. Maderazo EG, Judson S, Pasternak H. Late infections of total joint prostheses. A review and recommendations for prevention. Clinical Orthopaedics and Related Research. 1988;(229):131–142
  29. Bauer TW, Parvizi J, Kobayashi N, Krebs V. Diagnosis of periprosthetic infection. The Journal of Bone and Joint Surgery. American Volume. 2006;88:869–882
  30. Meehan AM, Osmon DR, Duffy MC, et al. Outcome of penicillin-susceptible streptococcal prosthetic joint infection treated with debridement and retention of the prosthesis. Clinical Infectious Diseases. 2003;36(7):845–849
  31. Tattevin P, Cremieux AC, Pottier P, et al. Prosthetic joint infection: when can prosthesis salvage be considered?. Clinical Infectious Diseases. 1999;29(2):292–295
  32. Brandt CM, Sistrunk WW, Duffy MC, et al. Staphylococcus aureus prosthetic joint infection treated with debridement and prosthesis retention. Clinical Infectious Diseases. 1997;24(5):914–919
  33. Tigges S, Stiles RG, Roberson JR. Appearance of septic hip prostheses on plain radiographs. American Journal of Roentgenology. 1994;163(2):377–380
  34. Stumpe KD, Notzli HP, Zanetti M, et al. FDG PET for differentiation of infection and aseptic loosening in total hip replacements: comparison with conventional radiography and three-phase bone scintigraphy. Radiology. 2004;231(2):333–341
  35. Zimmerli W, Ochsner PE. Management of infection associated with prosthetic joints. Infection. 2003;31(2):99–108
  36. Corstens F, van der Meer J. Nuclear medicine's role in infection and inflammation. Lancet. 1999;354:765–770
  37. Smith SL, Wastie ML, Forster I. Radionuclide bone scintigraphy in the detection of significant complications after total knee joint replacement. Clinical Radiology. 2001;56(3):221–224
  38. Ivancevic V, Perka C, Hasart O, et al. Imaging of low-grade bone infection with a technetium-99m labelled monoclonal anti-NCA-90 Fab' fragment in patients with previous joint surgery. European Journal of Nuclear Medicine and Molecular Imaging. 2002;29(4):547–551
  39. Love C, Pugliese PV, Afriyie MO, et al. 5. Utility of F-18 FDG imaging for diagnosing the infected joint replacement. Clinical Positron Imaging. 2000;3(4):159
  40. Shih LY, Wu JJ, Yang DJ. Erythrocyte sedimentation rate and C-reactive protein values in patients with total hip arthroplasty. Clinical Orthopaedics and Related Research. 1987;(225):238–246
  41. Trampuz A, Hanssen A, Osmon D, et al. Synovial fluid leukocyte count and differential for the diagnosis of prosthetic knee infection. The American Journal of Medicine. 2004;117:556–562
  42. Hughes JG, Vetter EA, Patel R, et al. Culture with BACTEC Peds Plus/F bottle compared with conventional methods for detection of bacteria in synovial fluid. Journal of Clinical Microbiology. 2001;39(12):4468–4471
  43. Pandey R, Berendt AR, Athanasou NA. Histological and microbiological findings in non-infected and infected revision arthroplasty tissues. The OSIRIS Collaborative Study Group. Oxford Skeletal Infection Research and Intervention Service. Archives of Orthopaedic and Trauma Surgery. 2000;120(10):570–574
  44. Atkins BL, Athanasou N, Deeks JJ, et al. Prospective evaluation of criteria for microbiological diagnosis of prosthetic joint infection at revision arthroplasty. The OSIRIS Collaborative Study Group. Journal of Clinical Microbiology. 1998;36(10):2932–2939
  45. Spangehl MJ, Masri BA, O'Connell JX, Duncan CP. Prospective analysis of preoperative and intraoperative investigations for the diagnosis of infection at the sites of two hundred and two revision total hip arthroplasties. The Journal of Bone and Joint Surgery. American Volume. 1999;81(5):672–683
  46. Widmer AF. New developments in diagnosis and treatment of infection in orthopedic implants. Clinical Infectious Diseases. 2001;33(supplement 2):S94–S106
  47. Widmer AF, Frei R, Rajacic Z, Zimmerli W. Correlation between in vivo and in vitro efficacy of antimicrobial agents against foreign body infections. The Journal of Infectious Diseases. 1990;162(1):96–102
  48. Widmer AF, Wiestner A, Frei R, Zimmerli W. Killing of nongrowing and adherent Escherichia coli determines drug efficacy in device-related infections. Antimicrobial Agents and Chemotherapy. 1991;35(4):741–746
  49. Zimmerli W, Frei R, Widmer AF, Rajacic Z. Microbiological tests to predict treatment outcome in experimental device-related infections due to Staphylococcus aureus. The Journal of Antimicrobial Chemotherapy. 1994;33(5):959–967
  50. Zimmerli W, Widmer AF, Blatter M, et al. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. The Journal of the American Medical Association. 1998;279(19):1537–1541
  51. Widmer AF, Gaechter A, Ochsner PE, Zimmerli W. Antimicrobial treatment of orthopedic implant-related infections with rifampin combinations. Clinical Infectious Diseases. 1992;14(6):1251–1253
  52. Zimmerli W. Modèles d'infection sur corps étranger. Médecine et Maladies Infectieuses. 1997;27(Spécial):181–187
  53. Trebse R, Pisot V, Trampuz A. Treatment of infected retained implants. The Journal of Bone and Joint Surgery. British Volume. 2005;87(2):249–256
  54. Shirtliff ME, Calhoun JH, Mader JT. Comparative evaluation of oral levofloxacin and parenteral nafcillin in the treatment of experimental methicillin-susceptible Staphylococcus aureus osteomyelitis in rabbits. The Journal of Antimicrobial Chemotherapy. 2001;48(2):253–258
  55. Greenberg RN, Newman MT, Shariaty S, Pectol RW. Ciprofloxacin, lomefloxacin, or levofloxacin as treatment for chronic osteomyelitis. Antimicrobial Agents and Chemotherapy. 2000;44(1):164–166
  56. Frippiat F, Meunier F, Derue G. Place of newer quinolones and rifampicin in the treatment of Gram-positive bone and joint infections. The Journal of Antimicrobial Chemotherapy. 2004;54(6):1158;[author reply 1159]
  57. Drancourt M, Stein A, Argenson JN, et al. Oral treatment of Staphylococcus spp. infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin. The Journal of Antimicrobial Chemotherapy. 1997;39(2):235–240
  58. Trampuz A, Zimmerli W. New strategies for the treatment of infections associated with prosthetic joints. Current Opinion in Investigational Drugs. 2005;6(2):185–190
  59. Drew RH, Perfect JR, Srinath L, et al. Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group. The Journal of Antimicrobial Chemotherapy. 2000;46(5):775–784
  60. Razonable RR, Osmon DR, Steckelberg JM. Linezolid therapy for orthopedic infections. Mayo Clinic Proceedings. 2004;79(9):1137–1144
  61. Bressler AM, Zimmer SM, Gilmore JL, Somani J. Peripheral neuropathy associated with prolonged use of linezolid. The Lancet Infectious Diseases. 2004;4(8):528–531
  62. Latronico N, Fenzi F, Recupero D, et al. Critical illness myopathy and neuropathy. Lancet. 1996;347(9015):1579–1582
  63. Carpenter CF, Chambers HF. Daptomycin another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clinical Infectious Diseases. 2004;38(7):994–1000
  64. Tsukayama DT, Wicklund B, Gustilo RB. Suppressive antibiotic therapy in chronic prosthetic joint infections. Orthopedics. 1991;14(8):841–844
  65. Tsukayama DT, Estrada R, Gustilo RB. Infection after total hip arthroplasty. A study of the treatment of one hundred and six infections. The Journal of Bone and Joint Surgery. American Volume. 1996;78(4):512–523
  66. Schoifet SD, Morrey BF. Treatment of infection after total knee arthroplasty by debridement with retention of the components. The Journal of Bone and Joint Surgery. American Volume. 1990;72(9):1383–1390
  67. Crockarell JR, Hanssen AD, Osmon DR, Morrey BF. Treatment of infection with debridement and retention of the components following hip arthroplasty. The Journal of Bone and Joint Surgery. American Volume. 1998;80(9):1306–1313
  68. Deirmengian C, Greenbaum J, Lotke PA, et al. Limited success with open debridement and retention of components in the treatment of acute Staphylococcus aureus infections after total knee arthroplasty. The Journal of Arthroplasty. 2003;18(7 supplement 1):22–26
  69. Marculescu CE, Berbari EF, Hanssen AD, et al. Outcome of prosthetic joint infections treated with debridement and retention of components. Clinical Infectious Diseases. 2006;42(4):471–478
  70. Berbari EF, Osmon DR, Duffy MC, et al. Outcome of prosthetic joint infection in patients with rheumatoid arthritis: the impact of medical and surgical therapy in 200 episodes. Clinical Infectious Diseases. 2006;42(2):216–223
  71. Ure KJ, Amstutz HC, Nasser S, Schmalzried TP. Direct-exchange arthroplasty for the treatment of infection after total hip replacement. An average ten-year follow-up. The Journal of Bone and Joint Surgery. American Volume. 1998;80(7):961–968
  72. Hope PG, Kristinsson KG, Norman P, Elson RA. Deep infection of cemented total hip arthroplasties caused by coagulase-negative staphylococci. The Journal of Bone and Joint Surgery. British Volume. 1989;71(5):851–855
  73. Raut VV, Siney PD, Wroblewski BM. One-stage revision of infected total hip replacements with discharging sinuses. The Journal of Bone and Joint Surgery. British Volume. 1994;76(5):721–724
  74. Langlais F. Can we improve the results of revision arthroplasty for infected total hip replacement?. The Journal of Bone and Joint Surgery. British Volume. 2003;85(5):637–640
  75. Westrich G, Salavati E, Braus B. Postoperative infection. In:  Bono JV,  McCarty JC,  Thornhill TS,  Bierbam E,  Turner RH editor. 1st edn. New York, NY: Springer-Verlag; 1999;p. 371–390
  76. Colyer RA, Capello WN. Surgical treatment of the infected hip implant. Two-stage reimplantation with a one-month interval. Clinical Orthopaedics and Related Research. 1994;(298):75–79
  77. van de Belt H, Neut D, Schenk W, et al. Infection of orthopedic implants and the use of antibiotic-loaded bone cements. A review. Acta Orthopaedica Scandinavica. 2001;72(6):557–571
  78. Josefsson G, Gudmundsson G, Kolmert L, Wijkstrom S. Prophylaxis with systemic antibiotics versus gentamicin bone cement in total hip arthroplasty. A five-year survey of 1688 hips. Clinical Orthopaedics and Related Research. 1990;(253):173–178
  79. Suter F, Avai A, Fusco U, et al. Teicoplanin versus cefamandole in the prevention of infection in total hip replacement. European Journal of Clinical Microbiology & Infectious Diseases. 1994;13(10):793–796
  80. Hill C, Flamant R, Mazas F, Evrard J. Prophylactic cefazolin versus placebo in total hip replacement. Report of a multicentre double-blind randomised trial. Lancet. 1981;1(8224):795–796
  81. Nelson CL, Green TG, Porter RA, Warren RD. One day versus seven days of preventive antibiotic therapy in orthopedic surgery. Clinical Orthopaedics and Related Research. 1983;(176):258–263
  82. Gatell JM, Garcia S, Lozano L, et al. Perioperative cefamandole prophylaxis against infections. The Journal of Bone and Joint Surgery. American Volume. 1987;69(8):1189–1193
  83. Wymenga A, van Horn J, Theeuwes A, et al. Cefuroxime for prevention of postoperative coxitis. One versus three doses tested in a randomized multicenter study of 2,651 arthroplasties. Acta Orthopaedica Scandinavica. 1992;63(1):19–24
  84. Mauerhan DR, Nelson CL, Smith DL, et al. Prophylaxis against infection in total joint arthroplasty. One day of cefuroxime compared with three days of cefazolin. The Journal of Bone and Joint Surgery. American Volume. 1994;76(1):39–45
  85. Nungu KS, Olerud C, Rehnberg L, et al. Prophylaxis with oral cefadroxil versus intravenous cefuroxime in trochanteric fracture surgery. A clinical multicentre study. Archives of Orthopaedic and Trauma Surgery. 1995;114(6):303–307
  86. Ahlberg A, Carlsson AS, Lindberg L. Hematogenous infection in total joint replacement. Clinical Orthopaedics and Related Research. 1978;(137):69–75
  87. Steckelberg J, Osmon D. Prosthetic joint infection. In:  Bisno AL,  Waldvogel FA editor. Infections Associated with Indwelling Medical Devices. 3rd edn. Washington, DC: American Society for Microbiology; 2000;p. 173–209
  88. Pallasch T, Wahl M. Focal infection: new age or ancient history. Endodontic Topics. 2003;4:32–45
  89. American Academy of Orthopaedic Surgeons. Antibiotic prophylaxis for dental patients with total joint replacement. Document no. 1014. http://www.aaos.org/wordhtml/papers/advistmt/1014.htm
  90. American Academy of Orthopaedic Surgeons. Antibiotic prophylaxis for urological patients with total joint replacements. Document no. 1023. http://www.aaos.org/wordhtml/papers/advistmt/1023.htm

PII: S1521-6942(06)00107-0

doi: 10.1016/j.berh.2006.08.003

Best Practice & Research Clinical Rheumatology
Volume 20, Issue 6 , Pages 1045-1063 , December 2006

Article Tools

* Image Usage & Resolution